Table 1.

BRAF and NRAS mutations in melanoma specimens: relationship with time to progression

Patient no.BRAFNRASTime to progression while on 17-AAG (mo)
20WTG13D49
24V600EWT2
25V600EWT1.5
26WTWT1.5
27V600EWT15
28WTWT1
  • NOTE: Six patients with metastatic malignant melanoma were treated with 17-AAG at doses of 320 to 450 mg/m2/wk. The time to progression on treatment along with BRAF and NRAS mutation status are summarized.